NodThera is unlocking the significant therapeutic potential of the NLRP3 inflammasome. A differentiated portfolio targets chronic inflammatory diseases of both the body and brain to realize the immense opportunity at hand for patient impact.
Building on our knowledge of the medicinal chemistry, biological activity and mechanism of action of NLRP3 inflammasome inhibitors, we are creating a next-generation pipeline of small molecules that are optimized for potency, PK and tissue penetration. We are also focusing on structural attributes that enable individual candidate molecules to be targeted to specific disease indications.
We have advanced our lead development candidate into a Phase 1 clinical trial. This first-in-human clinical study is evaluating the candidate for safety and tolerability as well as pharmacokinetic and pharmacodynamic response. We are also advancing our pipeline of other small molecule NLRP3 inhibitors — including compounds that cross the blood-brain barrier — and further progressing our drug discovery efforts.